Clavanin A Improves Outcome of Complications from Different Bacterial Infections

Mice, Inbred C57BL 0301 basic medicine Mice Staphylococcus aureus 03 medical and health sciences Anti-Infective Agents Escherichia coli Animals Blood Proteins Staphylococcal Infections Peptides Escherichia coli Infections 3. Good health
DOI: 10.1128/aac.03732-14 Publication Date: 2014-12-30T08:32:47Z
ABSTRACT
The rapid increase in the incidence of multidrug-resistant infections today has led to enormous interest antimicrobial peptides (AMPs) as suitable compounds for developing unusual antibiotics. In this study, clavanin A, an peptide previously isolated from marine tunicate Styela clava, was selected a purposeful molecule that could be used controlling infection and further synthesized. Clavanin A vitro evaluated against Staphylococcus aureus Escherichia coli well toward L929 mouse fibroblasts skin primary cells (SPCs). Moreover, challenged here vivo wound sepsis model, immune response also analyzed. Despite displaying clear activity Gram-positive -negative bacteria, showed no cytotoxic activities mammalian cells, acute toxicity tests, adverse reaction observed at any concentrations. significantly reduced S. CFU experimental model. This mortality mice infected with E. by 80% compared control animals (treated phosphate-buffered saline [PBS]): these data suggest prevents start thereby reduces mortality. These is AMP improve development novel peptide-based strategies treatment infections.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (41)
CITATIONS (41)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....